Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report 2026

The warm autoimmune hemolytic anemia (waiha) treatment market size has grown strongly in recent years. It will grow from $0.6 billion in 2025 to $0.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to reliance on corticosteroid therapy, limited treatment options, hospital-based autoimmune care, blood transfusion dependency, low disease awareness.

The warm autoimmune hemolytic anemia (waiha) treatment market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to biologic drug innovation, improved autoimmune diagnostics, expansion of precision medicine, growing geriatric population, specialty hematology care growth. Major trends in the forecast period include increased use of monoclonal antibody therapies, rising adoption of steroid-sparing treatments, expansion of personalized autoimmune therapies, growing role of ivig in acute management, improved diagnostic and monitoring protocols.

The rising healthcare expenditure is expected to drive the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market in the coming years. Healthcare expenditure refers to the total resources spent on health services, including prevention, diagnosis, treatment, and disease management, by individuals, governments, and organizations. Advances in medical technology are contributing to higher healthcare spending, as newer diagnostic tools and treatments often involve significant development, implementation, and ongoing patient care costs. Healthcare expenditure supports WAIHA treatment by funding research, improving access to advanced diagnostic tools, and ensuring the availability of specialized therapies to manage and control the disease. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that in real terms, long-term health and social care expenditures increased by 2.8% in 2022, while overall healthcare spending grew by 5.6% in 2023. Consequently, rising healthcare expenditure is driving the growth of the WAIHA treatment market.

Key companies in the WAIHA treatment market are focusing on developing innovative therapies, such as monoclonal antibodies, to address unmet clinical needs and improve patient outcomes. Monoclonal antibodies are laboratory-engineered proteins that target specific immune cells or pathways to reduce the destruction of red blood cells in WAIHA. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for IASO-782 Injection for use in clinical studies for autoimmune hematological conditions in the United States, including WAIHA and primary immune thrombocytopenia (ITP). Targeting CD19, this fully human monoclonal antibody includes Fc mutations to enhance ADCC activity while retaining other Fc functions. It selectively depletes CD19+ B cells, plasma blasts, and some plasma cells responsible for producing auto-reactive antibodies, offering a targeted approach for treating autoimmune diseases such as ITP and AIHA.

In September 2023, Zenas BioPharma Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb to develop and distribute obexelimab, an antibody used to treat autoimmune diseases. The collaboration aims to develop and commercialize effective new treatments for autoimmune diseases in key Asia-Pacific markets, addressing unmet medical needs and improving patient outcomes. Bristol Myers Squibb is a US-based pharmaceutical company specializing in WAIHA treatment.

Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the WAIHA treatment market by increasing the cost of importing biologics, plasma-derived IVIG, and specialized pharmaceutical ingredients used in monoclonal antibodies and corticosteroids. These higher costs have impacted hospital pharmacies and intravenous treatment segments the most, particularly in North America and Europe, which rely heavily on global biologics supply chains. However, tariffs are also encouraging regional production of immune therapies and plasma products, improving supply security and long-term treatment availability.

The warm autoimmune hemolytic anemia (waiha) treatment market research report is one of a series of new reports that provides warm autoimmune hemolytic anemia (waiha) treatment market statistics, including warm autoimmune hemolytic anemia (waiha) treatment industry global market size, regional shares, competitors with a warm autoimmune hemolytic anemia (waiha) treatment market share, detailed warm autoimmune hemolytic anemia (waiha) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the warm autoimmune hemolytic anemia (waiha) treatment industry. This warm autoimmune hemolytic anemia (waiha) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Warm autoimmune hemolytic anemia (WAIHA) treatment centers on controlling the immune system’s abnormal activity that attacks and destroys red blood cells at normal body temperature. The main objectives are to reduce or stop this immune-mediated destruction, restore healthy red blood cell levels, and relieve symptoms such as fatigue, shortness of breath, and pallor.

The primary treatments for WAIHA include corticosteroids, monoclonal antibodies, intravenous immunoglobulin (IVIG), blood transfusions, and splenectomy. Corticosteroids are anti-inflammatory drugs that suppress the immune system and reduce inflammation. They can be administered orally, intravenously, or subcutaneously, and are used for children, adults, and geriatric patients. Applications include primary autoimmune disorders, secondary autoimmune disorders, and cases with genetic predisposition. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The warm autoimmune hemolytic anemia (WAIHA) treatment market consists of revenues earned by entities by providing services such as diagnostic testing services, immune system monitoring, personalized treatment planning and care coordination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The warm autoimmune hemolytic anemia (WAIHA) treatment market also includes sales of diagnostic kits, immunomodulatory agents, hematology analyzers and red blood cell monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.